Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?

Chiara Corti, Elham Sajjadi, Nicola Fusco

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The clinical management of cancers has progressed rapidly into the immunopathology era, with the unprecedented histology-agnostic approval of pembrolizumab in mismatch repair (MMR) deficient tumors. Despite the significant recent achievements in the treatment of these patients, however, the identification of clinically relevant subclasses of cancers based on the MMR status remains a major challenge. Many investigations have assessed the role of different diagnostic tools, including immunohistochemistry, microsatellite instability, and tumor mutational burden in both prognostic and therapeutic settings, with heterogenous results. To date, there are no tumor-specific guidelines or companion diagnostic tests for MMR assessment, and this analysis is often performed with locally developed methods. In this review, we provide a comprehensive overview of the current state-of-knowledge of MMR alterations in syndromic and sporadic tumors and discuss the available armamentarium for MMR pathologic characterization, from morphology to high-throughput molecular tools.

Original languageEnglish
Pages (from-to)270-279
JournalAdvances in Anatomic Pathology
Volume26
Issue number4
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

DNA Mismatch Repair
Neoplasms
Microsatellite Instability
Tumor Burden
Routine Diagnostic Tests
Histology
Immunohistochemistry
Guidelines
Therapeutics

Keywords

  • biomarkers
  • cancer
  • immunohistochemistry
  • microsatellite instability
  • mismatch repair
  • mutations
  • next-generation sequencing
  • TMB

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance : Does One Size Fit All? / Corti, Chiara; Sajjadi, Elham; Fusco, Nicola.

In: Advances in Anatomic Pathology, Vol. 26, No. 4, 01.01.2019, p. 270-279.

Research output: Contribution to journalReview article

@article{fb6ded80145441c5973a01672f4385b1,
title = "Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?",
abstract = "The clinical management of cancers has progressed rapidly into the immunopathology era, with the unprecedented histology-agnostic approval of pembrolizumab in mismatch repair (MMR) deficient tumors. Despite the significant recent achievements in the treatment of these patients, however, the identification of clinically relevant subclasses of cancers based on the MMR status remains a major challenge. Many investigations have assessed the role of different diagnostic tools, including immunohistochemistry, microsatellite instability, and tumor mutational burden in both prognostic and therapeutic settings, with heterogenous results. To date, there are no tumor-specific guidelines or companion diagnostic tests for MMR assessment, and this analysis is often performed with locally developed methods. In this review, we provide a comprehensive overview of the current state-of-knowledge of MMR alterations in syndromic and sporadic tumors and discuss the available armamentarium for MMR pathologic characterization, from morphology to high-throughput molecular tools.",
keywords = "biomarkers, cancer, immunohistochemistry, microsatellite instability, mismatch repair, mutations, next-generation sequencing, TMB",
author = "Chiara Corti and Elham Sajjadi and Nicola Fusco",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/PAP.0000000000000234",
language = "English",
volume = "26",
pages = "270--279",
journal = "Advances in Anatomic Pathology",
issn = "1072-4109",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance

T2 - Does One Size Fit All?

AU - Corti, Chiara

AU - Sajjadi, Elham

AU - Fusco, Nicola

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The clinical management of cancers has progressed rapidly into the immunopathology era, with the unprecedented histology-agnostic approval of pembrolizumab in mismatch repair (MMR) deficient tumors. Despite the significant recent achievements in the treatment of these patients, however, the identification of clinically relevant subclasses of cancers based on the MMR status remains a major challenge. Many investigations have assessed the role of different diagnostic tools, including immunohistochemistry, microsatellite instability, and tumor mutational burden in both prognostic and therapeutic settings, with heterogenous results. To date, there are no tumor-specific guidelines or companion diagnostic tests for MMR assessment, and this analysis is often performed with locally developed methods. In this review, we provide a comprehensive overview of the current state-of-knowledge of MMR alterations in syndromic and sporadic tumors and discuss the available armamentarium for MMR pathologic characterization, from morphology to high-throughput molecular tools.

AB - The clinical management of cancers has progressed rapidly into the immunopathology era, with the unprecedented histology-agnostic approval of pembrolizumab in mismatch repair (MMR) deficient tumors. Despite the significant recent achievements in the treatment of these patients, however, the identification of clinically relevant subclasses of cancers based on the MMR status remains a major challenge. Many investigations have assessed the role of different diagnostic tools, including immunohistochemistry, microsatellite instability, and tumor mutational burden in both prognostic and therapeutic settings, with heterogenous results. To date, there are no tumor-specific guidelines or companion diagnostic tests for MMR assessment, and this analysis is often performed with locally developed methods. In this review, we provide a comprehensive overview of the current state-of-knowledge of MMR alterations in syndromic and sporadic tumors and discuss the available armamentarium for MMR pathologic characterization, from morphology to high-throughput molecular tools.

KW - biomarkers

KW - cancer

KW - immunohistochemistry

KW - microsatellite instability

KW - mismatch repair

KW - mutations

KW - next-generation sequencing

KW - TMB

UR - http://www.scopus.com/inward/record.url?scp=85063729782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063729782&partnerID=8YFLogxK

U2 - 10.1097/PAP.0000000000000234

DO - 10.1097/PAP.0000000000000234

M3 - Review article

AN - SCOPUS:85063729782

VL - 26

SP - 270

EP - 279

JO - Advances in Anatomic Pathology

JF - Advances in Anatomic Pathology

SN - 1072-4109

IS - 4

ER -